BIOFORCE NANOSCIENCES HOLDINGS, INC. (BFNH)
Laboratory Analytical Instruments · Laboratory Analytical Instruments · OTC
$4.00
+4.17%
Investingg Score
51.0 / 100
Hold
Business overview
- Gross margin of 24.5%
- Operating margin of -261.8%
Together, these figures reflect a stark contrast between top-line pricing capability and heavy operational losses that weigh on overall business quality.
Financial health
- Balance Sheet pillar score of 60
- Financial Quality pillar score of 25
These scores indicate a moderate baseline of balance sheet strength offset by weak underlying financial quality.
- Gross Margin
- 24.5%
- Operating Margin
- -261.8%
- Current Ratio
- 5.1x
- Debt / Equity
- Data unavailable
- Free Cash Flow (TTM)
- Data unavailable
- Interest Coverage
- Data unavailable
Valuation
- Price-to-sales ratio of 2623.14
- Valuation pillar score of 35
- P/E ratio, forward P/E, EV to EBITDA, and FCF yield are Data unavailable.
These figures highlight an extremely high price-to-sales ratio and a weak valuation score, suggesting substantial pricing concerns though several traditional valuation metrics are missing.
- P/E (TTM)
- Data unavailable
- Forward P/E
- Data unavailable
- Price / Sales
- 2623.1x
- EV / EBITDA
- Data unavailable
- FCF Yield
- Data unavailable
Key risks
- Operating margin is deeply negative at -261.8%, indicating heavy underlying losses.
- RSI stands at an extremely high 96.46, pointing to severe overbought technical conditions.
- Price-to-sales ratio is exceptionally elevated at 2623.14.
Market cap $61,082,352 · data as of 2026-08-19
Get the full interactive report
Technicals, earnings history, news, bull/base/bear scenarios, Ask the Stock, and more — free to start.
Analyze BFNH with Investingg AINot investment advice. Investingg AI summarizes public data and AI-generated analysis for informational purposes only.